A5023426618- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Sarcoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Pain Management and Opioid Use
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Gastrointestinal Tumor Research and Treatment
- Cancer survivorship and care
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- DNA Repair Mechanisms
- Estrogen and related hormone effects
- Ubiquitin and proteasome pathways
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Taipei Veterans General Hospital
2016-2025
National Yang Ming Chiao Tung University
2016-2025
National Yang Ming University Hospital
2004-2019
National Taipei University
2011-2019
Chinese PLA General Hospital
2018
Bridge University
2016
National Hsinchu University of Education
2016
Palmetto Hematology Oncology
2012
Chang Gung University
2002
Chang Gung Memorial Hospital
2002
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
Triple-negative breast cancer (TNBC) relapses more frequently than hormone receptor-positive subtypes and is often associated with poor outcomes.This retrospective study reviewed the pattern of distant metastasis regard to survival in patients TNBC.A total 205 TNBC were analyzed.TNBC lung metastases had longest median post-metastatic OS (with 95% confidence interval) 16.6 (10.3-22.9)months, followed by bone, 16.3 (11.7-20.8)months, liver, 8.9 (3.5-14.4)months, pleura, 7.5 (2.8-12.3)months,...
Abstract Purpose: We hypothesized that a window period between bevacizumab and cytotoxic agents may enhance drug delivery into tumor tissue through bevacizumab-induced vascular normalization in patients with brain metastases of breast cancer (BMBC). Experimental Design: A single-arm phase II study was conducted which BMBC refractory to whole-brain radiotherapy (WBRT) were enrolled. In 21-day cycle, received (15 mg/kg) on day 1, which, 1-day period, followed by etoposide (70 mg/m2/day; days...
Background Brain metastasis is a major complication of breast cancer. This study aimed to analyze the effect age and biological subtype on risk timing brain in cancer patients. Patients Methods We identified subtypes invasive ductal carcinoma by determining estrogen receptor, progesterone receptor HER2 status. Time according was analyzed Cox proportional hazard analysis. Results Of 2248 eligible patients, 164 (7.3%) developed over median follow-up 54.2 months. Age 35 or younger,...
The aim of this study was to examine the sonographic features phyllodes tumors breast.Retrospective analysis prospectively recorded performed on 2268 patients with or fibroadenomas during 1995-98. Data from 110 (76 benign, 11 borderline, 23 malignant) and 2204 were analyzed.The older than fibroadenoma (mean +/- standard error, 39.7 1.1 years vs. 33.4 0.3 years; P < 0.0001). Sixty-four percent aged 31-50 years, while 68.5% those 21-40 years. Phyllodes larger (5.90 0.43 cm 1.95 0.03 cm; ratio...
Background The important role of self-efficacy in facilitating health behavior and, turn, promoting outcomes has been widely presumed the theoretical literature. However, little research focused on mechanism by which self-care mediates relationship between symptom-management and quality life (QOL) breast cancer patients. Objective purpose this study was to examine Taiwanese oncology outpatients with then proposes as a mediator these two factors. Methods This cross-sectional enrolled 201 at...
The incidence of brain metastasis is increasing in patients with metastatic breast cancer. Treatments to extend the control are urgently required.
Theory has suggested that self-efficacy plays an important role in facilitating health behaviors and, turn, promoting healthy outcomes. However, limited research focused on the mechanisms through which symptom-management acts as a mediator between symptom distress and quality of life (QOL) for patients with breast cancer who have undergone chemotherapy.The purpose this study is to examine association QOL among Taiwanese oncology outpatients proposed QOL.This cross-sectional included 201 1...
Background: Neoadjuvant systemic therapy (NST) is conducted in increased number of patients with breast cancer overexpressing human epidermal growth factor receptor 2 (HER2). Whether the intensity HER2 protein expression determines response to treatment challenged. This study aims analyze impact immunohistochemical (IHC) scores on NST and survival outcome. Methods: We analyzed a total 197 HER2-positive receiving definite surgery from prospectively collected database. The endpoints included...
The aim of this study was to elucidate molecular profiling in HER2-low tumors based on a promising dataset. A total 615 consecutive HER2-negative breast cancer samples were assayed. genomic mutations the two groups with different HER2 expression levels (HER2-0 vs. HER2-low) compared. mutation types obtained via next-generation targeted sequencing correlated clinicopathological features patients HER2-0 and cancer. results showed that there significantly higher percentage receptor-positive...
Abstract Aims: Colorectal carcinoma in patients under 40 years of age usually has a poor prognosis. Controversies still exist regarding the features and prognosis colorectal cancer young patients. Methods: The records 45 with histologically confirmed treated between 1992 2002 at Division Oncology Taipei Veterans General Hospital were reviewed. relevance sex, duration symptoms, tumor site, histological type, lymph node involvement, Karnofsky performance status (KPS), carcinoembryonic antigen...
Surgery is the potentially curative treatment for retroperitoneal sarcoma (RS), but complete resectability frequently a challenge. This study aimed to characterize clinical features, prognostic factors and outcomes.A cohort of 144 patients with RS was surveyed retrospectively from January 1st, 2000 July 30th, 2011. The influence clinicopathological characteristics as well treatments on local recurrence-free survival (LRFS), distant metastasis-free (DMFS), overall (OS), were examined by...
While mutations in the PIK3CA gene play important roles human breast carcinogenesis, PIK3R1 alterations are recognized as actionable for clinical cancer treatment. We aimed to elucidate role of cell proliferation on carcinoma and correlate expression with patients' outcome using tumor tissue arrays. Using BT-474 (estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)-high) line vitro model, was elucidated by knock-down (ΔPIK3R1) this line. Between January 2000 December 2015, records...
Introduction: Despite rapidly improving therapeutics, challenges remain in the treatment of advanced breast cancer. Vinorelbine, a semisynthetic vinca alkaloid, is effective and well-tolerated cancer treatment. The combination vinorelbine platinum-combination but underreported chemotherapy regimen. Bevacizumab, VEGF-neutralizing antibody, has shown efficacy HER2-negative metastatic (mBC) when combined with chemotherapy. In this study we aimed to investigate clinical molecular effects...
Purpose: We aimed to identify genetic alterations in groups with different HER2 immunohistochemical (IHC) scores. Patients and Methods: A total of 120 patients HER2-positive breast cancers, including 89 cases IHC 3+ tumors 31 2+ positive for situ hybridization (ISH) were enrolled. Molecular profiles determined using Thermo Fisher TMO comprehensive assay on surgically removed tissues. All called variants compared between IHC3+ IHC2+/ISH+ by exact test. Results: There was a significantly...
The binary classification of human epidermal growth factor receptor 2 (HER2) as HER2-positive [immunohistochemistry (IHC) 2+/in situ hybridization (ISH)+ or 3+] HER2-negative (IHC 0, 1+, 2+/ISH-) has been reassessed due to the efficacy an anti-HER2 antibody-drug conjugate-Trastuzumab Deruxtecan in HER2-low 1+ unresectable/metastatic breast cancer (mBC) patients. However, little is known about prevalence and outcomes mBC Taiwan. This retrospective study rescored archived HER2 IHC slides...
Ferroptosis is a form of necrotic cell death characterized by phospholipid oxidation. The cystine-glutamate antiporter (xCT), composed solute carrier family 7 member 11 (SLC7A11) and SLC3A2, imports cystine for glutathione synthesis. Glutathione peroxidase 4 (GPX4) requires to counteract lipid peroxidation prevent ferroptosis. Erastin, an xCT inhibitor, Ras-selective lethal small molecule 3 (RSL3), GPX4 suppress function induce Tumor protein p53 (TP53) has paradoxical role in ferroptosis...
Abstract CDK4/6 inhibitors are currently standard of care for advanced hormone positive (HR+) breast cancer, and CDK6 overexpression induces resistance against inhibitors. We incidentally discovered that a D224Y mutant mitigated this resistance. Mechanistic studies revealed resulted in suppressed apoptosis increased G1/S progression after treatment with inhibitors; these features were abolished when was overexpressed. APEX2- based proximity labeling proteomics overexpression, but not D224Y,...
Lamivudine has demonstrated efficacy in the treatment and prevention of hepatitis B virus (HBV) reactivation after hematopoietic stem cell transplantation (HSCT). However, most these studies involved short durations prophylaxis, so there is significant concern regarding lamivudine resistance patients. Between March 1984 November 2002, 71 HBV surface antigen–positive HSCT recipients, including a subgroup 16 who received pretransplantation therapy, which was continued into posttransplantation...